Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2007

SeqWright to Perform Sequencing and Analysis for Third Wave HPV Trial

  • Third Wave Technologies selected SeqWright to participate in the clinical trial for two human papillomavirus (HPV) screening products.

    SeqWright will perform all the sequencing and associated analyses in support of Third Wave’s HPV trial for evaluation of two new in vitro diagnostic molecular assays: a screening test for the detection of 14 high-risk types of HPV and a genotyping test to specifically detect and identify HPV types 16 and 18. These two HPV types have been identified as the cause of approximately 70% of cervical cancer cases.

    SeqWright's participation in this clinical trial will enable development and implementation of custom sequence analysis procedures, according to the companies.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »